English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Objective. To develop a targeted drug for the treatment of rheumatoid arthritis. Methods. In this study, methotrexate (MTX) was combined with glucosamine (Glu) and modified with folic acid (FA) to prepare folic acid-glucosamine/methotrexate polymer (FA-Glu/MTX). The stability, sustained release, cytotoxicity, and therapeutic effect were evaluated based on in vitro and in vivo experiments. Results. FA-Glu/MTX had good stability, sustained release, and low cytotoxicity. In addition, the results of in vivo experiments proved that compared with MTX, FA-Glu/MTX has a stronger therapeutic effect on RA and has certain targeting properties. Conclusion. FA-Glu/MTX is expected to become a new option for RA treatment.

Folic Acid Modified Glucosamine/Methotrexate Polymer Targeted Therapy for Rheumatoid Arthritis